Taek Sang Lee1, Jae Weon Kim2, Tae Jin Kim3, Chi Heum Cho4, Sang Young Ryu5, Hee-Sug Ryu6, Byoung Gie Kim7, Keun Ho Lee8, Yong Man Kim9, Soon-Beom Kang10. 1. Department of Obstetrics and Gynecology, Seoul Metropolitan Boramae Hospital, Republic of Korea. 2. Department of Obstetrics and Gynecology, Seoul National University Hospital, Republic of Korea. Electronic address: kjwksh@snu.ac.kr. 3. Department of Obstetrics and Gynecology, Cheil General Hospital, Republic of Korea. 4. Department of Obstetrics and Gynecology, Keimyung University Dongsan Medical Center, Republic of Korea. 5. Department of Obstetrics and Gynecology, Korea Cancer Center Hospital, Republic of Korea. 6. Department of Obstetrics and Gynecology, Ajou University Hospital, Republic of Korea. 7. Department of Obstetrics and Gynecology, Samsung Seoul Hospital, Republic of Korea. 8. Department of Obstetrics and Gynecology, Seoul St. Mary's Hospital, Republic of Korea. 9. Department of Obstetrics and Gynecology, Asan Medical Center, Republic of Korea. 10. Department of Obstetrics and Gynecology, Seoul National University Hospital, Republic of Korea.
Abstract
OBJECTIVES: The objective of this study was to determine whether ovarian preservation is feasible in younger endometrial cancer patients. METHODS: Endometrial cancer patients who underwent ovary-saving surgery were recruited from the tumor registries of 14 tertiary hospitals under the influence of the Korean Gynecologic Oncology Group (KGOG). Information regarding patient age, preoperative and intraoperative evaluations, pathologic reports, and follow-up results was abstracted from medical records. RESULTS: One hundred and seventy five patients were eligible for this study. Mean patient age at the time of surgery was 38.5+/-8.3 years (range 25-57). Ovary-preserving surgery was performed in 101 (57.7%) patients who desired to preserve their ovaries, incidentally in 69 (39.4%) patients with preoperative diagnoses other than endometrial carcinoma, and in 5 patients (2.9%) with unknown reasons. Median duration of follow-up was 55.0 months (range 6.2-180.0 months). Recurrence free survival and overall survival rates were 94.3 and 93.3%, respectively. Seven of the 175 (4.0%) patients had documented recurrence, and no recurrences were observed in stage I patients with endometrioid histology. All 7 recurrences had risk factors that could have reasonably explained recurrence, namely, non-endometrioid histology (4/7), deep myometrial invasion (5/7), cervical stromal invasion (4/7), and inadequate adjuvant treatment (4/7). No metachronous ovarian malignancy occurred during follow-up. Ten (5.8%) deaths occurred during follow-up; five resulted from disease recurrence, and 5 from non-disease related causes. CONCLUSION: Our findings suggest that ovarian preservation does not adversely impact the recurrence of early stage endometrial cancer.
OBJECTIVES: The objective of this study was to determine whether ovarian preservation is feasible in younger endometrial cancerpatients. METHODS:Endometrial cancerpatients who underwent ovary-saving surgery were recruited from the tumor registries of 14 tertiary hospitals under the influence of the Korean Gynecologic Oncology Group (KGOG). Information regarding patient age, preoperative and intraoperative evaluations, pathologic reports, and follow-up results was abstracted from medical records. RESULTS: One hundred and seventy five patients were eligible for this study. Mean patient age at the time of surgery was 38.5+/-8.3 years (range 25-57). Ovary-preserving surgery was performed in 101 (57.7%) patients who desired to preserve their ovaries, incidentally in 69 (39.4%) patients with preoperative diagnoses other than endometrial carcinoma, and in 5 patients (2.9%) with unknown reasons. Median duration of follow-up was 55.0 months (range 6.2-180.0 months). Recurrence free survival and overall survival rates were 94.3 and 93.3%, respectively. Seven of the 175 (4.0%) patients had documented recurrence, and no recurrences were observed in stage I patients with endometrioid histology. All 7 recurrences had risk factors that could have reasonably explained recurrence, namely, non-endometrioid histology (4/7), deep myometrial invasion (5/7), cervical stromal invasion (4/7), and inadequate adjuvant treatment (4/7). No metachronous ovarian malignancy occurred during follow-up. Ten (5.8%) deaths occurred during follow-up; five resulted from disease recurrence, and 5 from non-disease related causes. CONCLUSION: Our findings suggest that ovarian preservation does not adversely impact the recurrence of early stage endometrial cancer.
Authors: Koji Matsuo; Hiroko Machida; Rebecca L Stone; Pamela T Soliman; Premal H Thaker; Lynda D Roman; Jason D Wright Journal: Obstet Gynecol Date: 2017-08 Impact factor: 7.661